How to access Dayvigo for adult insomnia from Abu Dhabi: 2026 pathway via Cleveland Clinic Abu Dhabi sleep medicine, Maudsley Health, and DoH controlled-prescription pharmacy supply
*Clinically reviewed by Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last reviewed 2026-05-20.
Abu Dhabi's adult psychiatry and sleep medicine network is anchored on the Cleveland Clinic Abu Dhabi sleep medicine programme and behavioural health service (the emirate's reference programme with on-site polysomnography and integrated psychiatry), Sheikh Shakhbout Medical City (SSMC) sleep medicine and psychiatry, Sheikh Khalifa Medical City (SKMC), Burjeel Medical City psychiatry, NMC Royal Hospital, Mediclinic Airport Road, and Maudsley Health (NMC) Abu Dhabi for psychiatric services. Tawam Hospital is a paediatric and oncology-focused centre and is not the adult sleep medicine destination. Dayvigo (lemborexant) is the dual orexin receptor antagonist (DORA) from Eisai, approved by the FDA in December 2019 for insomnia in adults. Dayvigo is registered with the Emirates Drug Establishment (EDE) via Eisai Middle East; Abu Dhabi-emirate dispensing is coordinated through the Department of Health (DoH) Abu Dhabi, and the drug is generally treated as a controlled substance under UAE MOHAP controlled-drug schedules. For an Abu Dhabi-resident adult patient with diagnosed insomnia disorder where cognitive behavioural therapy for insomnia (CBT-I) has been offered or trialled and pharmacotherapy is on the table, the operational question is which prescribing centre fits the case, how the controlled-prescription form runs through the DoH-coordinated dispensing pathway, what the insurance pre-authorisation conversation looks like (Thiqa for nationals, Daman and commercial covers for residents), and how the medication fits into an Abu Dhabi family's life.
This page explains how the pathway works in 2026 for an Abu Dhabi-resident patient: who qualifies, where the prescription is written and filled, what the realistic out-of-pocket exposure band is in AED, what to monitor on therapy, and how the treatment plan fits into an Abu Dhabi family's life.
Why Dayvigo, and why now
Dayvigo is lemborexant, a competitive dual antagonist at orexin-1 and orexin-2 receptors. Blocking orexin at bedtime reduces wake-promoting drive and allows sleep. Second DORA on the US market after suvorexant (Belsomra); followed by daridorexant (Quviviq).
FDA December 2019. US DEA Schedule IV. EDE-registered via Eisai Middle East; UAE MOHAP controlled-drug classification. Pivotal SUNRISE-1 and SUNRISE-2 separated from placebo on latency to persistent sleep and wake after sleep onset.
For an Abu Dhabi-resident adult with diagnosed insomnia disorder, Dayvigo is one reasonable option. Class advantage over benzodiazepines and Z-drugs: lower amnesia, falls, and abuse-potential signal. Trade-off: 17 to 19 hour half-life and next-day residual sedation risk.
What Dayvigo is, in plain language
Oral tablet. 5 mg and 10 mg. Immediately before bed with at least 7 hours remaining for sleep. Avoid heavy meals before dosing. Onset 30 minutes. Starting 5 mg; max 10 mg. Patients 65 and over stay at 5 mg. Moderate hepatic impairment caps at 5 mg. Severe hepatic impairment contraindicated.
Eligibility at an Abu Dhabi psychiatry or sleep medicine clinic
1. Confirmed insomnia disorder by DSM-5 or ICSD-3. 2. OSA screening (STOP-BANG, Epworth, ISI). Polysomnography if STOP-BANG positive. 3. CBT-I conversation documented. 4. Baseline PHQ-9 and C-SSRS. 5. Substance use history. 6. CYP3A4 interaction screen. 7. Respiratory function review. 8. Hepatic function review. 9. Pregnancy and lactation screen. 10. Age and occupational screening (Abu Dhabi has a large workforce in safety-sensitive aviation, oil and gas, military, and security roles).
An Abu Dhabi patient should arrive with a sleep diary, medication and supplement list, substance use history, prior insomnia treatments, comorbid conditions, and insurance documentation (Thiqa for Emirati nationals; Daman and commercial covers for residents).
The Abu Dhabi prescribing and dispense picture, plainly
EDE-registered via Eisai Middle East. Abu Dhabi-emirate dispensing coordinated through DoH. UAE MOHAP controlled-drug classification; controlled-prescription form required for each dispense; dispensing pharmacy maintains a controlled-drug register entry.
1. Prescribing physician: a board-certified Abu Dhabi psychiatrist, sleep medicine specialist, neurologist with insomnia experience, or family physician with DoH controlled-prescription authority. Major centres: - Sleep medicine reference programme: Cleveland Clinic Abu Dhabi sleep medicine and behavioural health (the emirate's reference programme, with on-site polysomnography and integrated psychiatry). - Sleep medicine and psychiatry: SSMC sleep medicine and psychiatry, SKMC, Burjeel Medical City psychiatry, NMC Royal Hospital psychiatry, Mediclinic Airport Road psychiatry, Maudsley Health (NMC) Abu Dhabi. - Tawam EXCLUDED: paediatric and oncology-focused, not the adult sleep medicine destination. 2. Diagnostic workup: clinical diagnosis. Polysomnography at Cleveland Clinic Abu Dhabi sleep laboratory, SSMC sleep laboratory, or partnered sleep laboratories. 3. Insurance pre-authorisation: Thiqa for Emirati nationals (Daman administers); Daman commercial and other commercial covers (Oman Insurance, AXA Gulf, MetLife, Cigna, NEXtCARE, Bupa Global) for residents. Most plans cover hypnotic therapy with controlled-prescription documentation; per-dispense quantity caps and periodic reauthorisation are standard. 4. Pharmacy dispense: 30-day supply at an Abu Dhabi community pharmacy with DoH controlled-drug dispensing authority. Original controlled-prescription form presented for each dispense; controlled-drug register entry maintained. 5. Refill cycle: monthly with fresh controlled-prescription form.
The 2026 pathway, step by step
Week 0 to 1: Documentation pack with treating prescribing physician's office.
Week 1 to 2: CBT-I conversation.
Week 2 to 4: Insurance pre-authorisation review.
Week 4: First controlled-prescription written. Starting dose 5 mg at bedtime.
Week 4 to 6: Initial response assessment, sleep diary review, PHQ-9 and C-SSRS reassessment, bed-partner check for complex sleep behaviours and hallucinations.
Month 3 onwards: Maintenance, monthly controlled-prescription refill, periodic reassessment.
Cost expectation in AED
US Dayvigo list price (2026) approximately USD 350 to USD 450 per 30-day supply, annual USD 4,000 to USD 5,000 at list price.
At 2026 cross rates, a 30-day Dayvigo supply at USD 400 is approximately AED 1,470, annual cost at USD 4,800 is approximately AED 17,650.
For Emirati nationals with Thiqa, hypnotic therapy for documented insomnia disorder is typically covered. Daman and other commercial covers vary. Out-of-pocket exposure for a covered patient is generally a co-payment band in the AED 30 to 200 per month range. For cash-pay patients, the absolute cost is meaningfully lower than the specialty-tier biologics in the wider Reserve Meds catalog.
Monitoring on therapy
- Next-day residual sedation and driving: counsel at first prescription and at dose escalation. Abu Dhabi's workforce in safety-sensitive aviation (Etihad pilots and cabin crew), oil and gas, military, and security roles makes this conversation particularly important. - Complex sleep behaviours: counsel patient and bed-partner. Immediate discontinuation if any episode occurs. - Sleep paralysis and hallucinations: counsel at first prescription. - Depression and suicidality: PHQ-9 and C-SSRS at baseline, 4 to 6 week response visit, every 3 to 6 months on maintenance, and at any clinical change. - Sleep diary: continuous. - OSA reassessment: any new daytime sleepiness, witnessed apnoeas, or morning headaches. - Substance use reassessment: at each follow-up.
Religious, ethical, and family-logistics framing
Oral small molecule. No animal-source material. Halal and kosher acceptability are not in question. The classical Islamic jurisprudential framework for medication in meaningful functional impairment extends to insomnia pharmacotherapy.
Family-logistics dimension: monthly in-person controlled-prescription dispense with the original form, next-morning driving counselling with the bed-partner where present, and the substance-use conversation. Abu Dhabi psychiatry and sleep medicine services handle these with discretion as standard practice. The large workforce in safety-sensitive aviation, military, and oil-and-gas occupations makes the next-morning impairment counselling a particularly important conversation.
When Dayvigo is not the right call
- Narcolepsy (contraindication). - Severe hepatic impairment (Child-Pugh C; contraindication). - Active opioid, benzodiazepine, alcohol, or sedative-hypnotic use disorder. - Pregnancy and lactation. - Concurrent strong CYP3A4 inhibitor. - Safety-sensitive occupations where next-morning impairment is unacceptable. - Active untreated severe depression or active suicidal ideation. - Untreated OSA where treating the OSA may resolve the insomnia. - Patients who have not been offered CBT-I.
Alternatives in 2026: CBT-I (first-line), suvorexant (Belsomra), daridorexant (Quviviq, shorter half-life), low-dose doxepin, melatonin and ramelteon, zolpidem and other Z-drugs, trazodone and mirtazapine off-label, benzodiazepines (short-term or specific scenarios).
Reserve Meds does not promote one DORA over another. The clinical decision is the prescribing physician's.
What Reserve Meds does on this case
We are a US-based concierge coordinator. We are not the prescriber and not the dispensing pharmacy. On an Abu Dhabi Dayvigo case we build the documentation pack, submit first-review requests to the chosen prescribing centre, coordinate the CBT-I conversation, coordinate the DoH-regulated insurance pre-authorisation pathway, coordinate the controlled-prescription pathway with the prescribing office and the DoH-licensed dispensing pharmacy, set up the first 30-day dispense, organise the next-morning driving counselling and bed-partner safety counselling, and stay with the case through the first 3 to 6 months of dosing with handoff to the local psychiatrist or sleep medicine physician for ongoing surveillance. Clinical decisions remain with your treating psychiatrist or sleep medicine physician.
Composite case examples; no individual patient is depicted. This content is for general information and does not constitute medical advice. Reserve Meds is a US-based concierge coordinator; we are not the prescriber and not the dispensing pharmacy. Clinical decisions remain with your treating psychiatrist or sleep medicine physician.
Clinical and regulatory review: Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last medically reviewed: 2026-05-20.